新柏式薄层液基细胞学(TCT)联合HPV-DNA分型检测在宫颈癌筛查中的临床价值  

The clinical value of new Parker style TCT combined HPV- DNA genotyping in cervical cancer screening

作　　者：姜爱凤[1] 王以新[1] 杨敏京[1] 冯妍[1] 边连朵[1] 

机构地区：[1]首都医科大学附属北京安贞医院大屯社区卫生服务中心,北京100029

出　　处：《现代肿瘤医学》2015年第20期3015-3017,共3页Journal of Modern Oncology

基　　金：北京市科技局重点立项课题(编号:20140592)

摘　　要：目的:探讨新柏式薄层液基细胞学(TCT)联合HPV-DNA分型检测在宫颈癌筛查中的临床价值。方法:随机选取2011年4月-2014年4月于我院进行宫颈癌筛查的420例患者为研究对象。所有患者均进行TCT及HPV-DNA筛查,并同时进行宫颈组织活检进行最终确认。结果:TCT筛查结果显示:ASCUS(意义不明的不典型鳞状细胞)患者为175例,阳性比例为41.7%。病理组织筛查结果显示:CINⅠ为199例,阳性比例为47.4%。HPV-DNA共检出阳性患者180例,比例42.9%。临床症状越严重,HPV-DNA阳性率越高。TCT联合HPV-DNA筛查结果灵敏度较单独TCT和HPV-DNA筛查结果高,但特异性低,其阳性预测值和阴性预测值都较高,与病理结果筛查结果更为相似。结论:新柏式薄层液基细胞学(TCT)联合HPVDNA分型检测在宫颈癌筛查中灵敏度高和准确性较高。Objective:To explore the clinical value of new type of TCT Parker combined with HPV -DNA typing in detecting cervical cancer screening.Methods:Randomly selected 420 cases of cervical cancer screening patients, all patients underwent TCT and HPV -DNA screening,while cervical biopsy for final confirmation.Results:CT screening showed number of patients with ASCUS 175 cases,the positive ratio 41.7%.Pathology screening showed ≥CINⅠ 199 cases,the positive ratio 47.4%.HPV -DNA positive patients,180 cases were detected,the proportion of 42.9%.The more severe the illness was,the higher the positive rate of HPV -DNA was.Conclusion:The new Parker style TCT combined HPV -DNA genotyping in cervical cancer screening is with high sensitivity and high accuracy.

关 键 词：TCT HPV-DNA分型 宫颈癌筛查 临床价值 

分 类 号：R737.33[医药卫生—肿瘤]